Details of the Drug Reposition

General Information of This Drug (ID: DMF1RTW)

Drug Name
Lurtotecan   DMF1RTW
Synonyms
OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Discontinued in Phase 2 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lung cancer DISCM4YA 2C25.0 Discontinued in Phase 1 [2]
------------------------------------------------------------------------------------

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004939)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010410)